Study guide

10.2 Sepsis, Shock & Resuscitation

MRCPI in General Medicine Part I Written

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Exam Structure, Strategy & Foundation

1.1 MRCPI Part I Format, Scoring & Standard-Setting 1.2 RCPI BST Curriculum & Single-Best-Answer Exam Strategy

2 Chapter 2: Cardiology & Vascular Medicine

2.1 Acute Coronary Syndromes & Stable Angina 2.2 Tachyarrhythmias, Bradyarrhythmias & Channelopathies 2.3 Heart Failure & Valvular Heart Disease 2.4 Hypertension, Vascular & Pericardial Diseases

3 Chapter 3: Respiratory Medicine

3.1 Asthma, COPD & Airway Diseases 3.2 Pneumonia, Tuberculosis & Respiratory Infections 3.3 Interstitial Lung Disease & Pleural Disorders 3.4 Pulmonary Embolism, Pulmonary Hypertension & Sleep Apnoea

4 Chapter 4: Gastroenterology & Hepatology

4.1 Upper & Lower GI Disorders & Inflammatory Bowel Disease 4.2 Acute & Chronic Liver Disease 4.3 Pancreatitis, Biliary Tract & GI Bleeding 4.4 Malabsorption, GI Motility & Clinical Nutrition

5 Chapter 5: Nephrology & Acid-Base Disorders

5.1 Acute Kidney Injury & Glomerular Diseases 5.2 Chronic Kidney Disease & Renal Replacement Therapy 5.3 Electrolyte Imbalances & Acid-Base Disorders

6 Chapter 6: Endocrinology & Diabetes

6.1 Diabetes Mellitus & Metabolic Complications 6.2 Thyroid & Calcium Disorders 6.3 Adrenal, Pituitary & Endocrine Syndromes

7 Chapter 7: Rheumatology & Clinical Immunology

7.1 Inflammatory Arthritides 7.2 Systemic Autoimmune & Vasculitic Diseases 7.3 Metabolic Bone Disease & Clinical Immunology

8 Chapter 8: Haematology & Medical Oncology

8.1 Anaemias, Haemostasis & Thrombosis 8.2 Leukaemias, Lymphomas & Plasma Cell Disorders 8.3 Medical Oncology & Oncological Emergencies

9 Chapter 9: Neurology & Dermatology

9.1 Stroke & Cerebrovascular Diseases 9.2 Epilepsy, Headache & Movement Disorders 9.3 Neuromuscular & Peripheral Nerve Disorders 9.4 Cutaneous Manifestations of Systemic Disease

10 Chapter 10: Acute Medicine, Critical Care & Geriatrics

10.1 Acute Poisoning & Toxidromes 10.2 Sepsis, Shock & Resuscitation 10.3 Geriatric Syndromes, Frailty & Comprehensive Care

11 Chapter 11: Clinical Pharmacology & Therapeutics

11.1 Pharmacokinetics & Pharmacodynamics 11.2 High-Risk Drug Classes & Prescribing Safety 11.3 Adverse Drug Reactions & Drug Safety

12 Chapter 12: Basic Sciences, Biostatistics & Clinical Ethics

12.1 Applied Cardiovascular & Respiratory Physiology 12.2 Clinical Biochemistry, Molecular Genetics & Microbiology 12.3 Biostatistics, Evidence-Based Medicine & Ethics

10.2 Sepsis, Shock & Resuscitation

Key Takeaways Explain This Topic AI

Sepsis-3 defines sepsis as life-threatening organ dysfunction caused by a dysregulated host response to infection, operationalized as an acute change in total Sequential Organ Failure Assessment (SOFA) score ≥ 2 points, reflecting an in-hospital mortality rate > 10%.

Septic shock is clinically identified by persistent hypotension requiring vasopressors to maintain a mean arterial pressure (MAP) ≥ 65 mmHg AND a serum lactate > 2 mmol/L despite adequate fluid resuscitation, conferring hospital mortality exceeding 40%.

Initial resuscitation for sepsis-induced hypoperfusion requires administration of at least 30 mL/kg of balanced crystalloid (e.g., Plasma-Lyte or Ringer's lactate) within 3 hours of identification; saline 0.9% is associated with hyperchloraemic metabolic acidosis and acute kidney injury.

Noradrenaline (norepinephrine) is the first-line vasopressor of choice in septic shock, titrated to maintain MAP ≥ 65 mmHg; vasopressin (up to 0.03 units/min) should be added as a second-line agent rather than escalating noradrenaline to high doses.

Last updated: July 2026

  • 10.2 Sepsis, Shock & Resuscitation
  • Sepsis-3 Definitions & Pathophysiological Concepts

In 2016, the Third International Consensus Definitions for Sepsis and Septic Shock ( Sepsis-3 ) redefined sepsis as a life-threatening organ dysfunction caused by a dysregulated host response to infection. This definition shifted clinical practice away from the non-specific Systemic Inflammatory Response Syndrome ( SIRS ) criteria (fever, tachycardia, tachypnoea, leucocytosis), which lacked specificity for adverse clinical outcomes.

Organ dysfunction in Sepsis-3 is operationalized as an acute change in total Sequential Organ Failure Assessment (SOFA) score of ≥ 2 \ge 2 ≥ 2 points attributable to the underlying infection. A baseline SOFA score is assumed to be zero in patients without pre-existing organ dysfunction. An acute increase in SOFA score by ≥ 2 \ge 2 ≥ 2 points correlates with an in-hospital mortality rate exceeding 10 % 10\% 10% .

To facilitate rapid bedside identification of infected patients at risk of deterioration outside the intensive care unit (ICU), the quick SOFA (qSOFA) tool was introduced. A qSOFA score of ≥ 2 \ge 2 ≥ 2 incorporates three clinical parameters:

  • Respiratory rate ≥ 22 breaths/min \ge 22\text{ breaths/min} ≥ 22 breaths/min
  • Altered mental status (Glasgow Coma Scale score < 15 < 15 < 15 )
  • Systolic blood pressure ≤ 100 mmHg \le 100\text{ mmHg} ≤ 100 mmHg

While qSOFA is not a formal diagnostic criterion for sepsis, meeting ≥ 2 \ge 2 ≥ 2 qSOFA criteria indicates a high risk of adverse outcomes and mandates urgent diagnostic evaluation, blood cultures, serum lactate measurement, and close monitoring.

SOFA Domain 0 Points 1 Point 2 Points 3 Points 4 Points

Respiration PaO 2 / FiO 2 (kPa) \text{PaO}_2/\text{FiO}_2\text{ (kPa)} PaO 2 ​ / FiO 2 ​ (kPa) ≥ 53.3 \ge 53.3 ≥ 53.3 ( 400 mmHg 400\text{ mmHg} 400 mmHg ) < 53.3 < 53.3 < 53.3 ( 400 mmHg 400\text{ mmHg} 400 mmHg ) < 40.0 < 40.0 < 40.0 ( 300 mmHg 300\text{ mmHg} 300 mmHg ) < 26.7 < 26.7 < 26.7 ( 200 mmHg 200\text{ mmHg} 200 mmHg ) with ventilatory support < 13.3 < 13.3 < 13.3 ( 100 mmHg 100\text{ mmHg} 100 mmHg ) with ventilatory support

Coagulation Platelets ( × 10 9 / L ) \text{Platelets } (\times 10^9/\text{L}) Platelets ( × 1 0 9 / L ) ≥ 150 \ge 150 ≥ 150 < 150 < 150 < 150 < 100 < 100 < 100 < 50 < 50 < 50 < 20 < 20 < 20

Liver Bilirubin ( μ mol/L ) \text{Bilirubin } (\mu\text{mol/L}) Bilirubin ( μ mol/L ) < 20 < 20 < 20 20 − 32 20-32 20 − 32 33 − 101 33-101 33 − 101 102 − 204 102-204 102 − 204 > 204 > 204 > 204

Cardiovascular Hypotension / Vasopressors \text{Hypotension / Vasopressors} Hypotension / Vasopressors MAP ≥ 70 mmHg \text{MAP} \ge 70\text{ mmHg} MAP ≥ 70 mmHg MAP < 70 mmHg \text{MAP} < 70\text{ mmHg} MAP < 70 mmHg Dopamine ≤ 5 \le 5 ≤ 5 or Dobutamine (any dose) Dopamine > 5 > 5 > 5 , Noradrenaline ≤ 0.1 \le 0.1 ≤ 0.1 Dopamine > 15 > 15 > 15 , Noradrenaline > 0.1 > 0.1 > 0.1

CNS Glasgow Coma Scale \text{Glasgow Coma Scale} Glasgow Coma Scale 15 15 15 13 − 14 13-14 13 − 14 10 − 12 10-12 10 − 12 6 − 9 6-9 6 − 9 < 6 < 6 < 6

Renal Creatinine ( μ mol/L ) \text{Creatinine } (\mu\text{mol/L}) Creatinine ( μ mol/L ) < 110 < 110 < 110 110 − 170 110-170 110 − 170 171 − 299 171-299 171 − 299 300 − 440 300-440 300 − 440 or Urine < 500 mL/day < 500\text{ mL/day} < 500 mL/day > 440 > 440 > 440 or Urine < 200 mL/day < 200\text{ mL/day} < 200 mL/day

Septic shock represents a subset of sepsis in which underlying circulatory and cellular/metabolic abnormalities are severe enough to substantially increase mortality. Clinically, septic shock is defined by:

Persistent hypotension requiring vasopressors to maintain a mean arterial pressure (MAP) ≥ 65 mmHg \ge 65\text{ mmHg} ≥ 65 mmHg , AND

A serum lactate > 2.0 mmol/L > 2.0\text{ mmol/L} > 2.0 mmol/L despite adequate fluid resuscitation.

Patients meeting both criteria carry an in-hospital mortality rate exceeding 40 % 40\% 40% .

Classification & Hemodynamic Profiles of Shock

Shock is defined as systemic cellular hypoxia resulting from an imbalance between cellular oxygen delivery ( DO 2 \text{DO}_2 DO 2 ​ ) and oxygen demand ( VO 2 \text{VO}_2 VO 2 ​ ). Prompt identification of the physiological shock subtype is critical to direct resuscitation therapies.

Shock Class Primary Mechanism Preload (CVP / PAWP) Cardiac Output (CO / CI) Systemic Vascular Resistance (SVR) Mixed Venous Saturation ( ScvO 2 \text{ScvO}_2 ScvO 2 ​ )

Hypovolaemic Intravascular volume depletion (haemorrhage, dehydration) Decreased ( ↓ ↓ \downarrow\downarrow ↓↓ ) Decreased ( ↓ \downarrow ↓ ) Increased ( ↑ ↑ \uparrow\uparrow ↑↑ ) Decreased ( < 65 % < 65\% < 65% )

Cardiogenic Primary pump failure (MI, acute HF, arrhythmia, myocarditis) Increased ( ↑ ↑ \uparrow\uparrow ↑↑ ) Decreased ( ↓ ↓ \downarrow\downarrow ↓↓ ) Increased ( ↑ ↑ \uparrow\uparrow ↑↑ ) Decreased ( < 65 % < 65\% < 65% )

Distributive (Septic) Peripheral vasodilation & capillary leak Normal or Low ( ↓ \downarrow ↓ ) Increased or Normal ( ↑ \uparrow ↑ ) Decreased ( ↓ ↓ \downarrow\downarrow ↓↓ ) Increased ( > 70 % > 70\% > 70% )

Obstructive Extracardiac flow obstruction (PE, Tamponade, Tension PTX) Increased ( ↑ ↑ \uparrow\uparrow ↑↑ ) Decreased ( ↓ ↓ \downarrow\downarrow ↓↓ ) Increased ( ↑ ↑ \uparrow\uparrow ↑↑ ) Decreased ( < 65 % < 65\% < 65% )

Emergency Resuscitation & The Hour-1 Bundle

The Surviving Sepsis Campaign (SSC) mandates immediate operational execution of the Hour-1 Bundle upon recognizing sepsis or septic shock:

Measure Serum Lactate Level: Re-measure within 2 − 4 2-4 2 − 4 hours if initial lactate is > 2.0 mmol/L > 2.0\text{ mmol/L} > 2.0 mmol/L to guide lactate clearance resuscitation goals.

Obtain Blood Cultures Prior to Antibiotics: Draw two sets of blood cultures (aerobic and anaerobic) from separate peripheral sites and central venous lines without delaying antimicrobial therapy beyond 1 hour.

Administer Broad-Spectrum Antimicrobials: Initiate empirical intravenous coverage targeting likely bacterial or fungal pathogens within 1 hour of presentation.

Begin Rapid Fluid Resuscitation: Administer a minimum bolus of 30 mL/kg 30\text{ mL/kg} 30 mL/kg of IV balanced crystalloid solution within 3 hours for sepsis-induced hypoperfusion (hypotension or lactate ≥ 4.0 mmol/L \ge 4.0\text{ mmol/L} ≥ 4.0 mmol/L ).

Apply Vasopressors: Initiate vasopressor therapy during or immediately after fluid resuscitation if MAP remains < 65 mmHg < 65\text{ mmHg} < 65 mmHg .

Fluid Selection in Sepsis

Balanced crystalloids (Ringer's lactate or Plasma-Lyte) are preferred over 0.9 % 0.9\% 0.9% Sodium Chloride. Large volumes of 0.9 % 0.9\% 0.9% Saline induce hyperchloraemic metabolic acidosis, renal afferent arteriolar constriction, and an increased incidence of acute kidney injury requiring renal replacement therapy (SMART trial). Human Albumin (5%) should be considered in patients requiring substantial volumes of crystalloids to achieve volume status targets.

Vasoactive Therapeutics & Invasive Hemodynamic Monitoring

When fluid resuscitation fails to restore an adequate MAP, vasoactive drugs must be titrated via continuous infusion through a central venous catheter under invasive arterial line monitoring:

Noradrenaline (Norepinephrine): The first-line vasopressor in septic shock. Its potent α 1 \alpha_1 α 1 ​ -adrenergic agonist activity restores arteriolar tone and SVR, while minor β 1 \beta_1 β 1 ​ -adrenergic effects maintain stroke volume without excessive tachycardia.

Vasopressin: Added as a second-line non-adrenergic vasopressor at a fixed dose of 0.03 units/min 0.03\text{ units/min} 0.03 units/min to restore MAP and reduce noradrenaline dosage requirements ("noradrenaline-sparing").

Adrenaline (Epinephrine): Second-line or additive agent when noradrenaline fails to maintain target MAP, though it increases lactate production via skeletal muscle β 2 \beta_2 β 2 ​ -stimulation.

Dobutamine: Added in patients with persistent tissue hypoperfusion despite adequate intravascular volume and MAP, or when myocardial dysfunction (septic cardiomyopathy) causes low cardiac index.

Hemodynamic endpoints include targeting a MAP ≥ 65 mmHg \text{MAP} \ge 65\text{ mmHg} MAP ≥ 65 mmHg , urine output ≥ 0.5 mL/kg/hour \ge 0.5\text{ mL/kg/hour} ≥ 0.5 mL/kg/hour , and central venous oxygen saturation ( ScvO 2 \text{ScvO}_2 ScvO 2 ​ ) ≥ 70 % \ge 70\% ≥ 70% . Dynamic measures of fluid responsiveness—such as passive leg raise (PLR) testing or pulse pressure variation (PPV > 13 % > 13\% > 13% ) on invasive arterial line traces—are superior to static volumetric parameters (CVP).

Acute Respiratory Distress Syndrome (ARDS) Management

ARDS is a severe manifestation of sepsis-induced acute lung injury. According to the Berlin Definition , ARDS is diagnosed when acute hypoxaemic respiratory failure occurs within 7 days of a known clinical insult, presenting with bilateral pulmonary infiltrates on chest imaging not fully explained by cardiac failure or fluid overload.

Severity is stratified by the PaO 2 / FiO 2 \text{PaO}_2/\text{FiO}_2 PaO 2 ​ / FiO 2 ​ (P/F) ratio on positive end-expiratory pressure (PEEP) ≥ 5 cmH 2 O \ge 5\text{ cmH}_2\text{O} ≥ 5 cmH 2 ​ O :

Mild ARDS: 200 < P/F ≤ 300 mmHg 200 < \text{P/F} \le 300\text{ mmHg} 200 < P/F ≤ 300 mmHg ( 26.7 < P/F ≤ 40 kPa 26.7 < \text{P/F} \le 40\text{ kPa} 26.7 < P/F ≤ 40 kPa )

Moderate ARDS: 100 < P/F ≤ 200 mmHg 100 < \text{P/F} \le 200\text{ mmHg} 100 < P/F ≤ 200 mmHg ( 13.3 < P/F ≤ 26.7 kPa 13.3 < \text{P/F} \le 26.7\text{ kPa} 13.3 < P/F ≤ 26.7 kPa )

Severe ARDS: P/F ≤ 100 mmHg \text{P/F} \le 100\text{ mmHg} P/F ≤ 100 mmHg ( ≤ 13.3 kPa \le 13.3\text{ kPa} ≤ 13.3 kPa )

Lung-Protective Mechanical Ventilation Strategies

Low Tidal Volume Ventilation: Set initial tidal volume to 6 mL/kg 6\text{ mL/kg} 6 mL/kg of Predicted Body Weight (PBW) (range 4 − 8 mL/kg 4-8\text{ mL/kg} 4 − 8 mL/kg ), rather than actual weight, to prevent volutrauma and biotrauma.

Plateau Pressure ( P plat \text{P}_{\text{plat}} P plat ​ ) Restriction: Maintain peak inspiratory plateau pressure ≤ 30 cmH 2 O \le 30\text{ cmH}_2\text{O} ≤ 30 cmH 2 ​ O .

PEEP Titration: Apply higher PEEP levels ( 10 − 18 cmH 2 O 10-18\text{ cmH}_2\text{O} 10 − 18 cmH 2 ​ O ) using ARDSNet PEEP/ FiO 2 \text{FiO}_2 FiO 2 ​ titration tables to prevent alveolar collapse (atelectotrauma).

Permissive Hypercapnia: Accept respiratory acidosis ( pH ≥ 7.15 − 7.20 \text{pH} \ge 7.15-7.20 pH ≥ 7.15 − 7.20 ) to adhere to strict volume/pressure limits.

Advanced Rescue Therapies for Severe ARDS

Prone Positioning: Placing patients prone for ≥ 16 hours/day \ge 16\text{ hours/day} ≥ 16 hours/day significantly reduces 28-day mortality in severe ARDS ( P/F < 150 mmHg \text{P/F} < 150\text{ mmHg} P/F < 150 mmHg ) by homogenizing transpulmonary pressure gradients and improving ventilation-perfusion matching (PROSEVA trial).

Neuromuscular Blockade: Short-course continuous cisatracurium infusion ( 48 hours 48\text{ hours} 48 hours ) reduces ventilator dyssynchrony and metabolic demand in refractory hypoxaemia.

Veno-Venous Extracorporeal Membrane Oxygenation (VV-ECMO): Indicated for severe refractory hypercapnic respiratory acidosis ( pH < 7.15 \text{pH} < 7.15 pH < 7.15 ) or severe hypoxaemia ( P/F < 80 mmHg \text{P/F} < 80\text{ mmHg} P/F < 80 mmHg ) despite prone positioning and lung-protective ventilation.